Paper42318924
A multicentre evaluation of pharmacokinetic/pharmacodynamic target attainment of piperacillin and tazobactam and the association with clinical outcomes in critically ill patients with sepsis and septic shock.
Sulaiman H and 13 others. J Antimicrob Chemother, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. A multicentre evaluation of pharmacokinetic/pharmacodynamic target attainment of piperacillin and tazobactam and the association with clinical outcomes in critically ill patients with sepsis and septic shock. Papers, record 42318924. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42318924
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
A multicentre evaluation of pharmacokinetic/pharmacodynamic target attainment of piperacillin and tazobactam and the association with clinical outcomes in critically ill patients with sepsis and septic shock.
- PubMed
Topics20
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Piperacillin | Major topic |
| Anti-Bacterial Agents | Major topic |
| Penicillanic Acid | Major topic |
| Sepsis | Major topic |
| Shock, Septic | Major topic |
| Humans | |
| Female | |
| Critical Illness | |
| Middle Aged | |
| Aged | |
| Male | |
| Adult | |
| Prospective Studies | |
| Treatment Outcome | |
| Tazobactam | |
| Aged, 80 and over | |
| Young Adult | |
| Adolescent | |
| Plasma | |
| Piperacillin, Tazobactam Drug Combination |
Source PubMed
Grants9
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| APP2009736 | Australian National Health and Medical Research Council | PubMed | ||
| Advancing Queensland Clinical Fellowship | PubMed | |||
| PV023-2017 | University Malaya Private | PubMed | ||
| 82003860 | National Natural Science Foundation of China | PubMed | ||
| 2024SF-YBXM-277 | Key Research and Development Program of Shaanxi | PubMed | ||
| IIT Clinical Research Fund | PubMed | |||
| M097 | Hospital of Xi'an Jiaotong University | PubMed | ||
| FRGS16-048-0547 | Ministry of Higher Education of Malaysia | PubMed | ||
| APP2007007 | Australian National Health and Medical Research Council Centre of Research Excellence | PubMed |
Source PubMed
References34
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 39699210 | Population pharmacokinetics of piperacillin-tazobactam in the plasma and cerebrospinal fluid of critically ill patients. | Antimicrob Agents Chemother | 2025 | https://conductscience.org/library/papers/39699210 | PubMed |
| 2 | 29080413 | A UHPLC-MS/MS method for the simultaneous determination of piperacillin and tazobactam in plasma (total and unbound), urine and renal replacement therapy effluent. | J Pharm Biomed Anal | 2018 | https://conductscience.org/library/papers/29080413 | PubMed |
| 3 | 32150603 | The Effect of Renal Replacement Therapy and Antibiotic Dose on Antibiotic Concentrations in Critically Ill Patients: Data From the Multinational Sampling Antibiotics in Renal Replacement Therapy Study. | Clin Infect Dis | 2021 | https://conductscience.org/library/papers/32150603 | PubMed |
| 4 | 36272277 | The clinical and paraclinical effectiveness of four-hour infusion vs. half-hour infusion of high-dose ampicillin-sulbactam in treatment of critically ill patients with sepsis or septic shock: An assessor-blinded randomized clinical trial. | J Crit Care | 2023 | https://conductscience.org/library/papers/36272277 | PubMed |
| 5 | 39628093 | Utilizing an Opportunistic Clinical Study and Population-Based Pharmacokinetic Models to Identify Rational Empiric Dosing Regimens for Piperacillin-Tazobactam in Critically Ill Patients. | J Clin Pharmacol | 2025 | https://conductscience.org/library/papers/39628093 | PubMed |
| 6 | 9455502 | Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. | Clin Infect Dis | 1998 | https://conductscience.org/library/papers/9455502 | PubMed |
| 7 | 36633812 | Population Pharmacokinetics of Piperacillin/Tazobactam Across the Adult Lifespan. | Clin Pharmacokinet | 2023 | https://conductscience.org/library/papers/36633812 | PubMed |
| 8 | 37615245 | International consensus recommendations for the use of prolonged-infusion beta-lactam antibiotics: Endorsed by the American College of Clinical Pharmacy, British Society for Antimicrobial Chemotherapy, Cystic Fibrosis Foundation, European Society of Clinical Microbiology and Infectious Diseases, Infectious Diseases Society of America, Society of Critical Care Medicine, and Society of Infectious Diseases Pharmacists. | Pharmacotherapy | 2023 | https://conductscience.org/library/papers/37615245 | PubMed |
| 9 | 24080664 | Protein binding of β-lactam antibiotics in critically ill patients: can we successfully predict unbound concentrations? | Antimicrob Agents Chemother | 2013 | https://conductscience.org/library/papers/24080664 | PubMed |
| 10 | 26754759 | Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis. | Intensive Care Med | 2016 | https://conductscience.org/library/papers/26754759 | PubMed |
| 11 | 29091190 | Too much of a good thing: a retrospective study of β-lactam concentration-toxicity relationships. | J Antimicrob Chemother | 2017 | https://conductscience.org/library/papers/29091190 | PubMed |
| 12 | 26787689 | Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Piperacillin in an In Vitro Infection Model. | Antimicrob Agents Chemother | 2016 | https://conductscience.org/library/papers/26787689 | PubMed |
| 13 | 26903338 | The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). | JAMA | 2016 | https://conductscience.org/library/papers/26903338 | PubMed |
| 14 | 33558347 | Piperacillin-tazobactam versus meropenem for treatment of bloodstream infections caused by third-generation cephalosporin-resistant Enterobacteriaceae: a study protocol for a non-inferiority open-label randomised controlled trial (PeterPen). | BMJ Open | 2021 | https://conductscience.org/library/papers/33558347 | PubMed |
| 15 | 25823963 | Population pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese and nonobese patients. | J Clin Pharmacol | 2015 | https://conductscience.org/library/papers/25823963 | PubMed |
| 16 | 24429437 | DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients? | Clin Infect Dis | 2014 | https://conductscience.org/library/papers/24429437 | PubMed |
| 17 | 37384803 | Bacterial Resistance in Hospital-Acquired Infections Acquired in the Intensive Care Unit: A Systematic Review. | Acta Medica (Hradec Kralove) | 2023 | https://conductscience.org/library/papers/37384803 | PubMed |
| 18 | 25894901 | Population Pharmacokinetics and Pharmacodynamics of Piperacillin/Tazobactam in Patients with Nosocomial Infections. | Eur J Drug Metab Pharmacokinet | 2016 | https://conductscience.org/library/papers/25894901 | PubMed |
| 19 | 32383061 | Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper. | Intensive Care Med | 2020 | https://conductscience.org/library/papers/32383061 | PubMed |
| 20 | 40239817 | Continuous versus intermittent bolus dosing of beta-lactam antibiotics in a South African multi-disciplinary intensive care unit: A randomized controlled trial. | J Infect | 2025 | https://conductscience.org/library/papers/40239817 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42318924
GET https://conductscience.org/api/papers/v1/42318924/references?page=2